

FORM#PP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET No.	SERIAL NO.			
9896-000053/NP	10/511,718			
APPLICANT				
Jun Liu et al.				
FILING DATE	GROUP			
October 18, 2004	To Bo Assigned 164:			

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.						

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
/RSf.		WO 01/078774 A	10/01	WIPO		X	
/RS/2.		WO 00/11214 A	3/00	WIPO		X	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
Ref. Desig.	Examiner's Initials				
/R <b>9</b> /		TB Vaccines: Progress and Problems; Trends in Immunology, Volume 22, Issue 3, dated March 1, 2001, pages 160-168.			
/R <del>§</del> /		Long-Term Maintenance Bacille Calmette-Guerin Therapy in High-Grade Superficial Bladder Cancer; Urology, Volume 59, Issue 3, dated March 2002, pages 414-418.			
<b>3.</b> /RS/		Glutamine Synthetase of Mycobacterium Tuberculosis: Extracellular Release and Characterization of its Enzymatic Activity; Proc. Natl. Acad. Sci. USA, Volume 91, dated September 1994, pages 9342-9346.			
<b>4.</b> /RS/		An Inhibitor of Exported Mycobacterium Tuberculosis Glutamine Synthetase Selectively Blocks the Growth of Pathogenic Mycobacteria in Axenic Culture and in Human Monocytes: Extracellular Proteins as Potential Novel Drug Targets; Department of Medicine, University of California at Los Angeles School of Medicine, Volume 189, Number 9, dated May 3, 1999, pages 1425-1435.			
/RS.		Mycobacterium bovis BCG Vaccines Exhibit Defects in Alanine and Serine Catabolism; Infection and Immunity, February 2003, pages 708-716.			

Examiner:	/Rodney Swartz/	Date Considered:	03/29/2008